Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/21/15Cidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines
New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, commends the Infectious Diseases Society of America (IDSA) for new clinical guidelines that recognize the important role of echinocan... 
11/16/15Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results
-- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET -- SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced positive data from the company's Phase 1 single ascending dose (SAD) clinic... 
11/10/15Cidara Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference in London
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2015 Global Healthcare Conference in London. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 2:00 p.m. GMT (6:00 a.m. PT) on Thursday, November 19, 2015 in London. A live audio webcast and r... 
09/19/15Cidara Therapeutics Presents Results from Key Studies Evaluating Its Novel Echinocandin CD101 at ICAAC/ICC 2015
– New Data Support CD101’s Potential as a Potent Treatment for Serious Fungal Infections and Highlight Progress in Company’s Robust Antifungal Drug-Development Program – SAN DIEGO--(BUSINESS WIRE)--Sep. 19, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the presentation of preclinical data from studies demonstrati... 
08/11/15Cidara Reports Second Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three and six months ended June 30, 2015 and provided an update on its corporate activities and product pipeline. Second Quarter 2015 and Subsequent Highlights Initiated Phase 1 Study of Lead Antifungal Product Candidate CD101 IV: In August, Cida... 
08/10/15Cidara Therapeutics to Present Data from Antifungal Drug Development Programs at ICAAC/ICC 2015 Meeting
- Sixteen abstracts summarize evaluations of company's novel echinocandin CD101 and Cloudbreak™ immunotherapy platform - SAN DIEGO--(BUSINESS WIRE)--Aug. 10, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that results of nonclinical studies of two formulations of CD101, a novel echinocandin, will be presented at t... 
08/05/15Cidara Therapeutics to Present at the Wedbush PacGrow 2015 Healthcare Conference
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 12:45 p.m. EDT (9:45 a.m. PDT) on Wednesday, August 12, 2015 in New York. A live audio webcast and replay wil... 
08/03/15Cidara Therapeutics Initiates Phase 1 Study of Lead Antifungal Product Candidate CD101 IV
SAN DIEGO--(BUSINESS WIRE)--Aug. 3, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD101 IV in healthy subjects. “The advancement of our first product candidate into the clinic a... 
06/23/15Cidara Therapeutics Set to Join Russell Indexes
SAN DIEGO, June 23, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that it is set to join the Russell 3000®, Russell 2000®, and Russell Microcap® Indexes at the conclusion of the annual reconstitution of Russell indexes on June 26, 2015. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of the end of May, ranking t... 
05/21/15Cidara Reports First Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO, May 21, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the quarter ended March 31, 2015 and provided an update on its corporate activities and product pipeline. First Quarter 2015 and Subsequent Highlights Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations for CD101 IV by FDA:... 
05/11/15FDA Grants QIDP and Fast Track Designations to CD101 IV, Cidara Therapeutics’ Lead Antifungal Product Candidate
-CD101 IV designated for treatment of serious or life-threatening Candida infections- SAN DIEGO--(BUSINESS WIRE)--May 11, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the company’s lead antifungal product candidate, CD101 IV, as a Qualified Infectio... 
04/15/15Cidara Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the pricing of its initial public offering of 4,800,000 shares of common stock, an increase of 800,000 shares from the number of shares originally offered, at a public offering price of $16.00 per share. The shares are expected to begin trading on the NASDAQ Global Market today (Ap... 
03/16/15Robert Perez and Timothy Franson Join Cidara Board of Directors
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that Robert J. Perez and Timothy R. Franson, M.D., have joined the company’s Board of Directors.“Mr. Perez and Dr. Franson are recognized leaders in the biotechnology and pharmaceutical industries and bring a wealth of complimentary operational experience to our board,” said Jeff Stein, Ph.D., chief executive officer of Cidara. “I have had... 
02/11/15Cidara Completes $42 Million Private Series B Financing
Proceeds Will Advance Novel Anti-Infectives into Clinical Studies Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing. Participants in the financing comprise a syndicate of healthcare-dedicated institutional investors and include both new and existing investors in Cidara.“We appreciate the support and confidence demonstrated by our n... 
02/09/15Cidara Appoints Paul Daruwala to Chief Commercial Officer and James Balkovec to SVP of Research
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the appointments of Paul Daruwala as chief commercial officer and James Balkovec, Ph.D. as senior vice president, Research. Paul Daruwala has more than 22 years of experience in the biopharmaceutical industry and joins Cidara to lead commercial and business development strategy and execution. Paul joins Cidara from Bristol Myers Squ...